Ken Drazan, ArsenalBio CEO
September 4, 2024 03:35 AM EDTUpdated 06:45 AM
Financing
R&D

Cell ther­a­py start­up Ar­se­nal­Bio rais­es $325M as it runs ear­ly sol­id tu­mor tri­als

Kyle LaHucik

Senior Reporter

CAR-T cell ther­a­py start­up Ar­se­nal Bio­sciences has reeled in a $325 mil­lion Se­ries C as it works through two ear­ly-stage tri­als in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

SEC probe of Il­lu­mi­na’s Grail deal tar­gets sales fore­casts, sources say

Pfiz­er tees up Phase 3 test in weight man­age­ment — but in an un­ex­pect­ed area

Scor­pi­on de­tails ear­ly da­ta on tar­get­ed breast can­cer drug as it seeks to chal­lenge No­var­tis, Roche

Ar­bor Biotech­nolo­gies cuts ear­ly-stage dis­cov­ery work, lays off staff

Up­dat­ed: Bris­tol My­ers touts LAG-3 strat­e­gy in lung can­cer but da­ta caveats damp­en ex­cite­ment

Post-Hoc: Big promis­es built Mod­er­na. They might al­so be its un­do­ing

A service from the Financial Times